
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Stem cell gene transfer treats IL-1 immune diseases
Dysregulation of the interleukin-1 (IL-1) pathway leads to immune diseases that can result in chronic tissue and organ inflammation. Although IL-1...

European VCs join US$105m financing of US Mediar Thx
Fibrosis, triggered by inflammation or injury, results in an abnormal production of scar tissue that can lead to organ failure. Luckily, not all...

Collaboration to fight cancer
Cancer Research UK and UCB SA have announced to advance two cancer antibodies of the Brussels-based biopharma company to the clinical testing stage....

Insempra and Axxence launch alpha-ionone
Insempra GmbH has launched its first functional ingredient, a biotechnologically produced, 100% natural alpha-Ionone flavour and fragrance ingredient...

Sanofi's/Astazeneca's anti-RSV antibody highly effective
Reduced immunity in the wake of the COVID-19 pandemic has contributed to large surges in respiratory syncytial virus (RSV) infections. After...

Oculis lists at Nasdaq through SPAC merger
Upon closing of the $104m SPAC deal with European Biotech Acquisition Corp, Oculis had a pro-forma enterprise value of approximately $220m and a cash...